Related Experiment Video
Updated: May 9, 2026
06:24
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
Hepatic CYP3A expression and activity in low birth weight developing female rats
Zhi-Wei Zhu1, Shao-Qing Ni, Xiu-Min Wang
1Department of Children's Health and Care, Children's Hospital of Zhejiang University School of Medicine and Zhejiang Key Laboratory for Diagnosis and Therapy of Neonatal Diseases, Hangzhou 310003, China.
World Journal of Pediatrics : WJP
|August 10, 2013
Summary
Low birth weight (LBW) significantly impacts cytochrome P-450 3A (CYP3A) expression and activity in developing rats, particularly in early life. These findings are crucial for understanding drug metabolism in LBW infants.
Area of Science:
- Pharmacology
- Developmental Biology
- Toxicology
Background:
- Low birth weight (LBW) is a significant concern in neonatal health.
- Hepatic cytochrome P-450 3A (CYP3A) enzymes play a critical role in drug metabolism.
- The impact of LBW on CYP3A in developing organisms requires further investigation.
Purpose of the Study:
- To investigate the effects of LBW on hepatic CYP3A expression and activity in developing female rats.
- To determine how LBW influences CYP3A mRNA and protein levels, localization, and enzymatic activity during different developmental stages.
Main Methods:
- Pregnant rats were divided into nourished and under-nourished groups.
- Offspring were categorized into normal weight (NN) and low birth weight (LN) groups.
- CYP3A1 and CYP3A2 mRNA expression, protein localization, and activity were assessed at various time points.
Main Results:
- LBW led to significantly higher CYP3A1 mRNA expression on days 3, 21, and 56, and CYP3A2 mRNA on day 21.
- CYP3A1-positive hepatocyte frequency and intensity were lower in LBW rats on days 7 and 21.
- CYP3A2-positive hepatocyte frequency and intensity were higher in LBW rats on days 14 and 21, with significantly elevated CYP3A activity on day 3.
Conclusions:
- LBW markedly alters hepatic CYP3A expression and activity in developing rats, with effects most pronounced in early life.
- These alterations in CYP3A are critical for pharmacokinetic studies and drug dosing in LBW infants.
- Clinicians and researchers must consider LBW's influence on CYP3A when designing studies and interpreting data for drug prescription.
More Related Videos
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:58Cell Specific Gene Expression
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...